Core Insights - Elanco has received USDA approval for TruCan Ultra CIV, a vaccine designed to protect dogs from canine influenza and improve their respiratory health [1][4] - The vaccine is part of Elanco's Tru Portfolio, reinforcing the company's commitment to innovative animal health solutions [1][3] - The introduction of TruCan Ultra CIV aims to enhance the overall experience for pets and their owners during veterinary visits, reducing fear and anxiety associated with illness [4][3] Company Overview - Elanco Animal Health is a global leader in animal health, focusing on innovative products and services to prevent and treat diseases in both farm animals and pets [6][7] - The company has a 70-year heritage in animal health and is dedicated to creating value for various stakeholders, including farmers, pet owners, and veterinarians [6][7] Product Details - TruCan Ultra CIV has demonstrated effectiveness in protecting dogs' lungs and reducing viral shedding, with zero vaccinated dogs developing lung lesions post H3N2 challenge [6][7] - The vaccine is proven safe across multiple breeds and ages, addressing the needs of high-risk dog breeds, particularly brachycephalic breeds [2][6] - TruCan Ultra CIV is now available for pre-order and will ship within the next 30 business days [4]